Loading…
ELAB
PMGC Holdings Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 73017P508
$5.31-8.92%Price as of Aug 29, 18:50 UTC · updated once a day, after the close
Key metrics
- Market cap
- $4.3M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.2x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1,686.49
- ROE
- -105.22%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -0.25
- 52-week high
- $2,671.20
- 52-week low
- $5.24
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $355.20 | $13,498.95 | $2,155,115.75 | |
| P/S | — | 48.6x | — | — |
| P/B | 10.6x | 3.7x | 10.6x | 82.8x |
| EPS | -$380.99 | -$1,195.13 | -$29,262.02 | |
| Profit margin | — | -1313.00% | — | — |
| ROE | -98.86% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| APVOAptevo Therapeutics Inc. | $2.37 | 0.0x | 0.6x | — | -420.34% | $4.26M |
| XRTXXORTX Therapeutics Inc. | $2.34 | — | 1.6x | — | -99.24% | $4.25M |
| GRIGRI Bio, Inc. | $1.92 | — | 0.4x | — | -142.02% | $4.2M |
| XAIRBeyond Air, Inc. | $4.48 |
About the company
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
- 32
- Newport Beach, United States
Company description provided by Yahoo Finance.